Helena J. H. van der Pal

Helena J. H. van der Pal

Auto-generated profile, based on publicly available information

Helena J. H. van der Pal

Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HPHelena J. van der Pal
Helena J. van der Pal
EDElvira C. van Dalen
Elvira C. van Dalen
EDEvelien van Delden
Evelien van Delden
IDIrma W. van Dijk
Irma W. van Dijk
WKWouter E. Kok
Wouter E. Kok
LKLeontien C. Kremer
Leontien C. Kremer
Purpose: To evaluate the long-term risk for validated symptomatic cardiac events (CEs) and associated risk factors in childhood cancer survivors (CCSs). Patients and Methods: We determined CEs grade 3 or higher: congestive heart failure (CHF), cardiac ischemia, valvular disease, arrhythmia and/or pericarditis (according to Common Terminology Criteria for Adverse Events [CTCAE], version 3.0) in a hospital-based cohort of 1,362 5-year CCSs diagnosed between 1966 and 1996. We calculated both marginal and cause-specific cumulative incidence of CEs and cause-specific cumulative incidence of separate events. We analyzed different risk factors in multivariable Cox regression models. Results: Overall, 50 CEs, including 27 cases of CHF, were observed in 42 survivors (at a median attained age of 27.1 years). The 30-year cause-specific cumulative incidence of CEs was significantly increased after treatment with both anthracyclines and cardiac irradiation (12.6%; 95% CI, 4.3% to 20.3%), after anthracyclines (7.3%; 95% CI, 3.8% to 10.7%), and after cardiac irradiation (4.0%; 95% CI, 0.5% to 7.4%) compared with other treatments. In the proportional hazards analyses, anthracycline (dose), cardiac irradiation (dose), combination of these treatments, and congenital heart disease were significantly associated with developing a CE. We demonstrated an exponential relationship between the cumulative anthracycline dose, cardiac irradiation dose, and risk of CE. Conclusion: CCSs have a high risk of developing symptomatic CEs at an early age. The most common CE was CHF. Survivors treated with both anthracyclines and radiotherapy have the highest risk; after 30 years, one in eight will develop severe heart disease. The use of potentially cardiotoxic treatments should be reconsidered for high-risk groups, and frequent follow-up for high-risk survivors is needed.

26 July 2010 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
HPHelena J. van der Pal
Helena J. van der Pal
EDElvira C. van Dalen
Elvira C. van Dalen
MHMichael Hauptmann
Michael Hauptmann
WKWouter E. Kok
Wouter E. Kok
HCHuib N. Caron
Huib N. Caron
LKLeontien C. Kremer
Leontien C. Kremer
Long-term survival of childhood cancer has improved considerably, from 20% in the 1940s,1 to 70% to 80%2-5 at present, owing to chemotherapy, radiotherapy, supportive therapy, and combined modality treatment. Unfortunately, improved survival is accompanied by the occurrence of late treatment effects.6-8 Cardiovascular disease (CVD) and cardiac mortality are among the most serious late effects. Several population-based studies observed a 6- to 8-fold increased mortality owing to CVD among childhood cancer survivors (CCSs) compared with the general population.9-11

1 February 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
RMR.L. Mulder
R.L. Mulder
HPH.J.H. van der Pal
H.J.H. van der Pal
GLG.A. Levitt
G.A. Levitt
RSRoderick Skinner
Roderick Skinner
LKL.C.M. Kremer
L.C.M. Kremer
EFE. Frey
E. Frey

1 May 2005 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
HPHelena J.H. van der Pal
Helena J.H. van der Pal
EDElvira C. van Dalen
Elvira C. van Dalen
LKLeontien C.M. Kremer
Leontien C.M. Kremer
PBPiet J.M. Bakker
Piet J.M. Bakker
FLFlora E. van Leeuwen
Flora E. van Leeuwen

1 February 2022 in European Journal of Cancer
Verified
Journal Article
Open access
RKRebecca J. van Kalsbeek
Rebecca J. van Kalsbeek
RMRenée L. Mulder
Renée L. Mulder
RHRiccardo Haupt
Riccardo Haupt
MMMonica Muraca
Monica Muraca
LHLars Hjorth
Lars Hjorth
LKLeontine C.M. Kremer
Leontine C.M. Kremer
Long-term follow-up (LTFU) care, although endorsed, is not available for the majority of adult survivors of childhood, adolescence and young adult (CAYA) cancer. Barriers to implementation include lack of time, knowledge, personnel and funding. Sustainable solutions are urgently needed to address the needs of CAYA cancer survivors to improve the quality of life and reduce the burden of late effects on survivors, health care systems and society. The European Union-funded PanCareFollowUp project, initiated by the Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer, was established to facilitate the implementation of person-centred survivorship care across Europe. The PanCareFollowUp Care Intervention was co-developed with survivors as part of the PanCareFollowUp project. It is a person-centred approach to survivorship care, supported by guidelines and with flexibility to adapt to local health care settings. The Care Intervention consists of three steps: (1) previsit completion of a Survivor Questionnaire (by the survivor) and Treatment Summary (by the health care provider [HCP]), (2) a clinic visit including shared decision-making, and (3) a follow-up call to finalise the individualised Survivorship Care Plan. We developed the key components of the PanCareFollowUp Care Intervention: a PanCareFollowUp Survivor Questionnaire, Treatment Summary template, Survivorship Care Plan template, and educational materials for HCPs and survivors. Wide implementation of the PanCareFollowUp Care Intervention will be supported with a freely distributed Replication Manual on completion of the PanCareFollowUp project. The PanCareFollowUp Care Intervention will support the implementation of person-centred, guideline-based LTFU care in different health care settings across Europe to improve survivors' health and well-being.

20 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JSJuliette Stolze
Juliette Stolze
KVKim C. E. Vlaanderen
Kim C. E. Vlaanderen
FHFrederique C. E. D. Holtbach
Frederique C. E. D. Holtbach
JTJop Teepen
Jop Teepen
LKLeontien C.M. Kremer
Leontien C.M. Kremer
Henk BrandHenk Brand
Henk Brand
Objectives: The aim of this study was to identify the prevalence of and independent risk factors for long-term effects of childhood cancer treatment on the dentition and oral health in childhood cancer survivors (CCSs). Methods: This cross-sectional study is part of the Dutch Childhood Cancer Survivor Study (DCCSS) LATER 2. CCSs were diagnosed with cancer between 1963 and 2001. This study focuses on survey data of 154 CCSs on whom information about their oral health was received from their dentists (71.3%). Descriptive statistics and univariable and multivariable Poisson regression analyses were performed to determine the association between treatment characteristics and oral health data. Results: Of the study group, 36.3% had at least one DDD. The most prevalent DDDs were short-root anomaly (14.6%), agenesis (14.3%), and microdontia (13.6%). Risk factors for at least one DDD were younger age at diagnosis (<3 years) and dose-dependent alkylating agent therapy. Conclusions: This study provides more insight into risk factors for oral health problems in Dutch CCSs. This information is essential in order to improve early detection, prevention, dental care, and quality of life. Further studies are needed in order to better define dose-related radiotherapy exposure of the developing teeth in correlation with oral health problems.